Prognostic Value of PD-L1 in NSCLC

Fondazione Ricerca Traslazionale

Status: Unknown

Conditions: Carcinoma, Non-Small-Cell Lung

Treatments: Other: immunohistochemistry

Study type: Observational

Funder types: Other

Identifiers

NCT03078959

L3P1490

Details and patient eligibility

About

This is an observational retrospective study. The primary objective is to investigate the expression and potential prognostic role of Programmed Death Ligand 1 (PD-L1) in tumor samples from 350 patients with early stage treatment-naive non-small-cell lung cancer (NSCLC).

Tissue samples were embedded in a tissue microarray. PD-L1 will be studied by immunohistochemistry using the SP263 antibody. Stained samples will be evaluated independently by two operators. A tumor will be defined as positive when = or >50% of tumor cells express the ligand.

The investigators will investigate the relationship between PD-L1 protein expression and overall survival and other clinical characteristics with appropriate statistical methods.

Enrollment: 350 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Early stage treatment-naive NSCLC

Exclusion criteria

• Received any pre-surgical treatment
• no OS data available